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This article provides an extensive literature review on the changing role of users 
in innovation, with a particular focus on the healthcare sector. Users have been 
specifically analyzed by many scholars worldwide due to their significant role as a 
source of innovation beyond the traditional assumption which considers customers 
as mere passive adopters of products and services. The increasing, but still scarce, 
number of studies on this topic has demonstrated the benefits of patient involvement 
and how a close and continuous relationship between patients and practitioners can 
lead to permanent cycles of improvements and innovation in healthcare outcomes. In 
addition to a user-centered approach, innovative patients are actively developing new 
solutions for their own treatments, likewise for other patients with similar diseases.
Keywords: patient involvement, user innovation, user-centered innovation, interactive 
innovation, health innovation. 
INTRODUCTION
Innovation is an interactive process based on continuous knowledge flows 
between the innovative actor and its stakeholders (Chesbrough, 2003, 2011; 
Lundvall, 1988, 1992; Nelson, 1993). Latest studies have attempted to explain 
how many firms incorporate ideas, insights and knowledge from outside 
their own boundaries (Christensen & Lundvall, 2004; Gomes-Casseres, 
2003; Gutiérrez-Gracia & Fernández-de-Lucio, 2009; Powell & Grodal, 2005; 
Vega-Jurado). By providing a narrative review of the literature, this paper 
aims to explore the changing role of users in innovation, with a particular 
focus on the healthcare sector. Using a snowball sampling technique, special 
attention is given to the significance of multi-level collaboration among the 
manifold economic actors that compose the healthcare industry, especially 
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the experienti al knowledge and pati ent involvement along the process of 
medical research and innovati on.
Pati ents have increasingly played a signifi cant role in healthcare 
innovati on because their experience, practi cal knowledge and feelings can 
determine the way healthcare services are provided. Moreover, the new trend 
of customizati on of healthcare entails a high level of user involvement and 
constant informati on fl ows between pati ent and practi ti oners. The healthcare 
provision along an integrated pati ent journey enables practi ti oners to identi fy 
“experience-drivers, value-creati ng acti viti es and reasons for dissati sfacti on 
and complaints, ideas for service development and innovati on” (Echeverri et 
al., 2013, p. 50). 
Despite the steady evoluti on towards an evidence-based medicine, 
insuffi  cient att enti on has been paid in the existi ng innovati on literature to 
the acti ve performance of users in the public sector and especially in the 
healthcare industry. This scarcity opposes the statement that the importance 
of innovati on cannot be higher in any other sector than in healthcare since 
breakthroughs have the potenti al specifi c target to improve life quality, cure 
diseases and save human lives. 
In additi on to a user-centered approach, innovati ve pati ents are acti vely 
developing new soluti ons for their own treatments, likewise for other 
pati ents with similar diseases. User innovati on also plays a vital role in the 
healthcare sector as principal source of hope for the treatment of many 
illnesses, parti cularly orphan diseases (Habicht, Oliveira & Shcherbati uk, 
2012; Oliveira, Zejnilovic, Canhão & von Hippel, 2015). This evidence 
emphasizes the major value of experience-based learning embodied in the 
role of pati ents as innovators.
Figure 1. Synthesis of the paper’s structure
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As summarized in Figure 1, this paper starts with the fundamentals of 
interactive innovation and the importance of multi-level collaboration in 
healthcare services. Among all possible agents implicated in the healthcare 
delivery system, the subsequent section focuses exclusively on the involvement 
of patients in medical innovation. In the last section, we discuss the existence of 
user innovation initiatives, highlighting recent research on patient innovators. 
LITERATURE REVIEW
Fundamentals of interactive innovation 
Generations of innovation models have shown that innovation today emanates 
from an interactive, multidimensional, integrated, systemic and open process 
(Chesbrough, 2003; Chesbrough, Vanhaverbeke & West, 2006; Kline & 
Rosenberg, 1986; Lundvall, 1988, 1992; Nelson, 1993; Rothwell, 1992, 1994) 
in contrast to models where interactions are represented on a linear scale 
(technology-push and demand-pull). From a systemic perspective, innovation 
consists of a dynamic and interactive process of creative destruction since 
the relationship with other economic actors, and the knowledge exchange 
evoked from this interaction, is the heart of any kind of innovation. Empirical 
studies have demonstrated that enterprises rarely innovate in isolation of the 
economic system (Christensen & Lundvall, 2004). In this regard, cooperation 
and extramural knowledge exchange have become the basis of the innovation 
process in many companies. The traditional research and development 
activity (R&D) is complementary to many other sources of information such 
as internal and external partnerships and other types of collaboration which 
encompass a wide range of actors such as suppliers, customers, universities, 
technology institutes, government and so forth. 
This perspective has caused a significant shift towards a new way of 
understanding the complex process of innovation. In academia, a new wave 
of studies has revealed new dimensions including (a) the importance of tacit 
knowledge (Collins, 1974; Polanyi, 1967), (b) a new generation of dynamic 
models of innovation (Kline & Rosenberg, 1986; Rothwell, 1992, 1994), (c) 
the concept of techno-economics networks (Callon, 1991), (d) the conception 
of core competence (Leonard-Barton, 1992; Prahalad & Hamel, 1990), and 
especially (e) the role of lead users and customer-centered innovation (von 
Hippel, 1988; von Hippel, 2005; de Jong & von Hippel, 2009). As a result, 
new elements have emerged such as (1) the involvement of multiple agents 
along the innovation process, (2) the access to new knowledge through 
collaboration, (3) the important role of user experience and (4) the customer 
as co-creator.
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This new configuration has conditioned the design of new theoretical 
frameworks for economic and innovation policies such as (a) the evolutionary 
perspective (Nelson & Winter, 1982), which describes economic growth as 
dynamics and evolutionary process of knowledge accumulation and diffusion, 
(b) system failures (Metcalfe, 1995, 2003), understood as barriers to the 
innovation, (c) National System of Innovation (Edquist, 1997; Freeman, 1987a, 
b, 1995; Lundvall, 1992; Nelson, 1993), which applies a holistic approach to 
the innovation process, laying emphasis on the interaction among different 
economic actors at the hub of the analysis, (d) the Triple Helix model of 
knowledge creation (Etzkowitz & Leydesdorff, 1997, 2000; Leydesdorff & Meyer, 
2006) which focuses on the importance of interaction and communication 
among enterprises, universities and governmental institutions, and more 
recently (e) the Open Innovation Paradigm (Chesbrough, 2003; Chesbrough, 
Vanhaverbeke & West, 2006), which accentuates the increasing relevance of 
external (in addition to the internal) flows of knowledge as enhancement of 
internal innovation and commercialization of new ideas.
The change from a linear to multi-actor perspective points up the 
interactive and systemic nature of innovation as well as alternative modes 
of innovation based on learning by doing, using and interacting (e.g., 
Jensen, Johnson, Lorenz & Lundvall, 2007). This mode of innovation differs 
from the traditional understanding of an innovation process based highly 
on advancements and improvements derived exclusively from science and 
technology. While the former mode of innovation lays great emphasis on 
implicit, tacit knowledge and experience-based learning, the latter one 
put the accent on explicit, codified knowledge and on formal structures 
of knowledge transfer. The experiential expertise underlines the value of 
implicit, tacit knowledge and the process of learning by doing, using and, in 
the healthcare context, suffering. The user experience plays the role of a third 
element of a puzzle composed of two more types of knowledge: propositional 
knowledge (“knowing that”) and procedural knowledge (“knowing how”) 
(Caron-Flinterman, Broerse & Bunders, 2005). The next section goes into 
some critical factors that have influenced the development of healthcare 
activities and the way innovation has been conceived in this industry. 
Healthcare services and the collaborative nature of medical innovation
Healthcare and healthcare innovation in development
Several aspects have been transforming traditional medicine research and 
healthcare provision over the last few decades. The productivity crisis faced 
in the healthcare industry is certainly a key factor. Despite the rising share 
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of national output (% of GDP), productivity in the healthcare sector did not 
grow at the same pace, in part caused by the low level of standardization 
and the labor-intensive nature of its output (Baumol, 1967; Chesbrough, 
2011; Folland, Goodman & Stano, 2007). In the pharmaceutical industry 
in particular, the decline in R&D productivity is mainly a consequence of 
diminishing returns in the knowledge production function, more challenging 
therapeutic targets and excessive bureaucracy (LaMattina, 2011; Munos, 
2009; Pammolli, Magazzini & Riccaboni, 2011). The productivity crisis in this 
sector, and especially in the pharmaceutical realm (Hara, 2003), entailed 
innovation in multiple facets including incremental changes in internal and 
external R&D management, alternative drug development as well as the 
development of personalized, stratified and regenerative medicine (Mittra, 
2016). 
Another factor refers to the market access strategies and the patent 
conflict principally in pharmaceutical industry. As a critical instrument for 
intellectual property protection in several high tech industries, the patent 
system has played a pivotal role in healthcare, respectively in pharmaceutical 
R&D and innovation (Folland, Goodman & Stano, 2007; Grabowski & Vernon, 
1990; Grabowski, 2003). In the context of developing countries however, 
patents had made the prices of new drugs unaffordable. To ensure access 
to medicines in these countries, differential pricing has been ascribed as a 
possible approach to attend the needs in both high and low income markets 
in different countries (Danzon & Towse, 2003) and within-country via market 
segmentation (Yadav, 2010). 
A third aspect is related to the common practices of mergers and 
acquisitions (M&A) over the last decades in the pharmaceutical industry, 
which have shattered the R&D activities (LaMattina, 2011; see also Brown, 
Werling, Walker, Burgdorfer, & Shields, 2012, for M&A in the hospital 
industry). By studying the dynamics of drug innovation since 1950, Munos 
(2009) demonstrated that the number of new drug approvals is directly 
correlated to the number of firms involved. His results indicated that “M&A 
are not an effective way to promote an innovation culture or remedy a deficit 
of innovation” (Munos, 2009, p. 961). 
Other dominant trends encompass the progress of medical technologies 
(Spekowius & Wendler, 2006), the volatility of the healthcare market 
(Lebrecht, 2015), the patient’s perspective of healthcare (World Health 
Organization, 2007, 2013), the increase in collaborations and partnerships 
(Consoli & Ramlogan, 2009; Consoli & Mina, 2009), among others. In the 
next subsection we will focus on the collaborative nature of innovation in 
healthcare.
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Collaborative innovation in healthcare
The literature on innovation in the healthcare industry has highlighted the 
increasing importance of external mechanisms of knowledge integration and 
interfirm R&D collaboration between pharmaceuticals firms, universities 
and hospitals (Liebeskind, Oliver, Zucker & Brewer, 1996; Oliver, 2001; 
Orsenigo, Pammolli & Riccaboni, 2001; Quéré, 2004; Powell, 1990; Powell, 
Koput & Smith-Doerr, 1996; Powell, White, Koput & Owen-Smith, 2005; 
Rai, 2005; Shaw, 1998; Swan et al., 2005; Weigel, 2008) as well as in the 
context of biotechnology innovation (Broerse & Bunders, 2000; Roijakkers & 
Hagedoorn, 2006; Vence, Sánchez, Rodil, 2013). This evidence endorses the 
hypothesis that innovation, regardless of industry, relies to a great extent on 
the continuous and unbounded interaction among an array of actors. 
Medical innovation is a valuable example of where interactivity is 
represented at a multidimensional level in order to discover or improve 
treatments, therapies and drugs for a wide range of diseases. This collaborative 
character has increased significantly over the last decade, turning healthcare 
innovation into an extremely networked system (Consoli & Ramlogan, 2009). 
The literature aimed to stress that the role of collaborations and networks 
in the healthcare industry has become more widespread during the last 
decades (Cambrosio, Keating, Mercier, Lewison & Mogoutov, 2006; Consoli & 
Mina, 2009; Consoli & Ramlogan, 2009; Liebeskind et al., 1996; Oliver, 2001; 
Orsenigo, Pammolli & Riccaboni, 2001; Powell et al., 2005; Powell, 1990; 
Powell, Koput & Smith-Doerr, 1996; Quéré, 2004; Rai, 2005; Ramlogan, Mina, 
Tampubolon & Metcalfe, 2007; Shaw, 1998; Swan et al., 2005; Weigel, 2008). 
Consoli and Mina (2009) described the health innovation system as 
a structure composed of the health delivery system and the science and 
technological system. The constant interaction between both systems and 
the continuous flow of knowledge represents the basis of the innovation 
dynamic in this sector. The health delivery system consists of the service 
provision and the direct relationship between practitioner and patients. The 
science and technological system, on the other hand, is composed of the 
technological market, which is responsible for developing new drugs and 
medical devices, and the scientific community. Among all actors involved in 
healthcare provision and innovation, the next section considers exclusively 
the information and knowledge exchange between healthcare providers and 
patients in medical research and innovation.
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The user-centered paradigm and the involvement of patients in 
medical research and innovation
User-centered paradigm in healthcare services
Over the last decades, a new consumer-centric paradigm – where the users 
play an active and major role as co-developers and co-innovators – has 
questioned the real scope of the traditional manufacturing-active model 
(Baldwin & von Hippel, 2011; von Hippel, 1978a,b, 1986, 1988, 2005; von 
Hippel & Katz, 2002; von Hippel & de Jong, 2010). Among all economic agents 
involved in the innovation process, users have been specifically analyzed due 
to their remarkable role as source of innovation contributing with original 
ideas and experiential wisdom (von Hippel, 1988). Many authors have singled 
out the major value of experience-based learning and the value of users as an 
innovation source in several industries (Bower, 2005; Caron-Flinterman et al., 
2005; von Hippel, 1988, 2005; Jensen et al., 2007; Lundvall, 1985, 2006, 2007; 
Rabeharisoa, 2003; Smits & Boon, 2008). Nevertheless, an overview of these 
examples leads us to question whether user-centered innovation can also 
flourish in an industry such as healthcare whose innovation mode is highly 
based on science and technology. Empirical results show that clinicians can 
play a major role as lead users via field discovery. Demonaco, Ayfer and von 
Hippel (2006) have empirically confirmed that a significant number of drug 
therapy innovations were discovered by clinical practice, bridging practical 
experience with patients and the Science & Technology system. 
In the patient context, the user-driven innovation paradigm implies that 
the role of patients has changed from a passive subject of research to an 
active partner along the innovation process (Mittra, 2016). When the patient 
is involved, the relevance, the pragmatism as well as the benefits of the 
research in terms of usefulness, effectiveness and practical efficacy increase. 
However, evidence reveals that this involvement has mostly been focused 
on the decisions and the management of chronic illnesses than on research, 
development and innovation (Echeverri et al., 2013). Additionally, several 
health professionals are still averse to a closer doctor-patient relationship in 
certain areas including decision making and choice (Lester, Tait, England & 
Tritter, 2006; European Commission, 2012). 
The patient involvement in healthcare innovation was proved to be not 
only a buzzword but a challenging, though profitable, task (Kielstra, 2009; 
Trivedi & Wykes, 2002). The expert knowledge required and the patient’ low 
purchasing power have traditionally differentiated patients from consumers in 
other sectors. However, this panorama is gradually changing and the current 
evidence demonstrates that they can significantly influence innovation in 
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health services. Patients’ purchasing power has increased and they have 
become more concerned and knowledgeable about their own treatment and 
healing (Røtnes & Staalesen, 2009).
The conception of patient-centered healthcare systems in collaboration 
with other economic and societal actors can strengthen the prevention of 
lifestyle-related illnesses such as cardiovascular disease, cancer or diabetes 
(Echeverri et al., 2013). Besides, the fruitful implementation of patient-
focused care entails cooperation between providers, health plans, and 
policymakers (Reed, Conrad, Hernandez, Watts & Marcus-Smith, 2012). 
The alliance of several societal actors became a key strategy to stimulate 
and implement ideas and improvements derived from the close patient-
practitioner interaction. Indeed, a group of experts, in discussion on the 
future of healthcare in Sweden, have proposed the creation of a national 
incubator for patient innovation (Echeverri et al., 2013). Its responsibilities 
would include the compilation of innovation ideas from different healthcare 
organizations, assistance during the planning and implementation phase, as 
well as the link between private entrepreneurs and healthcare organisms. 
This proposal runs in parallel with the creation of a formal body of governance 
to operate all kind of initiatives including innovation instruments, knowledge 
management and dissemination of eHealth as well as social media. The 
following subsection describes the main attributes of patients that can 
determine the level of engagement.
Patient involvement: importance and characteristics
A recent qualitative survey performed across fifteen European Member 
States underlines that the concept of involvement is not entirely clear for 
both patients and practitioners, commonly seen as a mere compliance 
of treatments (European Commission, 2012; see also Sahlsten, Larsson, 
Sjostrom & Plos, 2008). User involvement in healthcare comprises different 
aspects compared to other traditional industries. Thanks to this fact, patient-
centered healthcare tends in general to integrate and involve patients 
instead of letting the patients lead the process (Røtnes & Staalesen, 2009). 
For particular disturbances such as stroke, however, lead user methods 
have been vastly applied to better comprehend how patients experience 
healthcare (Echeverri et al., 2013).
The engagement and the close cooperation with treatments were 
demonstrated to be more effective with enlightened and instructed patients. 
Particularly in hospitals, more than a few patients felt more comfortable to 
share their experience with nurses, whose relationship “is more likely to be 
characterized by trust and equality” (European Commission, 2012, p. 37). 
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Besides, the involvement is expected to be more intensive with chronically ill 
patients and those with orphan (rare) diseases (a small and specific market 
widely neglected by the pharmaceutical industry due to a lack of financial 
incentives). For these cases, patients are more aware of several aspects of 
the disease and more experienced in self-monitoring. Additionally, patients 
with chronic diseases are in general more conscious of alternative treatments 
(European Commission, 2012), which makes the experiential knowledge a 
major source of hope for the treatment of many illnesses. The patient’ age 
and likewise the patient’ socioeconomic status also contribute to the level 
of involvement. Empirical results reveal that younger patients with greater 
income and with greater educational skills are more likely to use touch screen 
technology, as a way to collect patient feedback data (Zarghom, Fonzo & 
Leung, 2013). The positive and negative outcomes from patient involvement 
in medical research are discussed in the next subsection. 
Patient involvement in medical research
The experiential knowledge has grown to be a key contribution of patients to 
medical research (Caron-Flinterman et al., 2005), providing expert information 
based on daily experience of their own diseases. This involvement certainly 
leads towards significant changes in the focus, in the design and also in the 
content of the research (Trivedi & Wykes, 2002). Pioneering initiatives in 
Nordic countries stress the emergence of new innovation trends toward the 
adoption of a user-led innovation in the entire public healthcare system, also 
in hospitals (Røtnes & Staalesen, 2009; Echeverri et al., 2013). In Sweden, 
most of the research councils have implemented research and innovation 
initiatives with a close patient involvement, involving an increase of patient 
value and costs reduction (Echeverri et al., 2013). Recent health studies and 
reports put emphasis on the increasing patients’ involvement in diagnosis, 
treatments, therapies and cure of diseases derived from (bio)medical 
research activities and clinical trials (National Institute for Health Research 
[NIHR], 2009). Patient-reported outcomes (PROs) is becoming a key element 
for clinical research, by providing physicians with different types of data and 
information such as “physical functions, symptoms, global judgments of 
health, psychological well-being, social well-being, cognitive functioning, role 
activities, personal constructs, satisfaction with care, health related quality of 
life [and] adherence to medical regimens” (Deshpande, Rajan, Sudeepthi & 
Abdul Nazir, 2011, p. 137).
A significant impact of experiential knowledge of patients was shown 
in different stages of the medical research, including the development of 
the grant application, the research design, the data analysis as well as the 
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dissemination of research findings (National Institute for Health Research 
[NIHR], 2010; see also Trivedi & Wykes, 2002). The following table summarizes 
the consecutive phases of medical research in which patients could be 
involved, and their possible contribution.
Table 1. User involvement in medical research
The stages of medical 
research 
The involvement of users can help:
The development of 
the grant application
To discuss the research idea and help to focus the question to one 
that reflects patients’ needs and will benefit patients.
To review the research proposal and offer suggestions from a patient 
perspective.
To help identify where users could be involved in other areas of the 
research project.
To be named as a co-applicant for funding and ethics approval.
The research design To identify areas where users could be involved in the research.
Inform the design of communication materials to better suit 
participants, for example:
by helping to make patient information sheets and consent forms 
more understandable,
by reviewing questionnaires and other data collection methods.
To identify possible participant recruitment strategies.
To consider the ethical implications of the research and help 
researchers to understand patient concerns and suggest ways to 
address these.
To provide an idea of what it is like to take part in research.
The research 
management
To identify ways to resolve problems in relation to recruiting or 
retaining participants, for example where to advertise and in what 
format.
The undertaking of 
the research
To undertake data collection.
The analysis of the 
research data
To suggest gaps in the data which can help identify further research 
questions.
To provide their interpretation of the data which may be different to 
that of the research team.
The dissemination of 
research findings
To advise and develop reports on the research findings that are 
understandable to the public.
To provide suggestions on where to disseminate the findings; who 
will be interested, how to reach them and in what format. For 
example, there may be a website forum where you can make your 
research known, or a patient group you could present to.
To participate in presenting the findings of the research and talk 
about their experience of being involved in the process.
Source: Own elaboration based on NIHR (2010).
Many authors have underlined numerous benefits from this close 
partnership among patients, practitioners and researchers. This involvement 
permits patients to improve their knowledge and research skills (Buckley, 
Grant, Firkins, Greene, & Frankau, 2007; Clark, Glasby & Lester, 2004; Griffiths, 
Jorm & Christensen, 2004), converting sick people into proto-professionals 
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(Caron-Flinterman et al., 2005), as well as to strengthen patient’ esteem 
and confidence (Clark, Glasby & Lester, 2004; McCormick, Brody, Brown 
& Polk, 2004; Minogue, Boness, Brown & Girdlestone, 2005). The benefits 
for patients also include a better understanding of the nature and purpose of 
the research carried out (Donovan et al., 2002) and the capacity to introduce 
real needs into the research’s objectives (Kent, 2002; Kent & Oosterwijk, 
2007; Wootton, Wood & Cook, 2008). The advantages also embrace a wider 
diffusion of findings and, evidently, an increased relevance of the research as 
well as the results obtained and the methods of analysis (Ali, Roffe & Crome, 
2006; Hanley, Truesdale, King, Elbourne & Chalmers, 2001; McCormick et 
al., 2004; Rose, 2003). In addition to the patient-centered care discussed 
hitherto, the next section examines the user innovation literature in the 
sphere of healthcare. 
User innovation in healthcare services
User innovation: concept and measurement
In several industries, best practices in business have increasingly 
demonstrated that profitable novel or enhanced products, processes and 
services were originally developed by users, so-called “lead users”. This class 
of users is composed not only of expert, senior professional advisors, but 
also amateur devotees, passionate insiders, customers and end-users, who 
are simply aiming to find solutions for their own needs. They are experience-
based experts with strong unsatisfied needs (von Hippel, 1986; Urban & von 
Hippel, 1988). 
To date, most of the empirical literature on user innovation has been 
based on in depth and thorough case studies. The list of examples is 
increasingly extensive and many empirical studies over the last few years 
have highlighted the existence of user innovation in different contexts such 
as printed circuit CAD software (Urban and von Hippel, 1988), pipe hanger 
hardware (Herstatt & von Hippel, 1992), new medical equipment technology 
or devices (Biemans, 1991; Lüthje, 2003; Lettl & Gemünden, 2005), outdoor 
consumer products (Lüthje, 2004), sport equipment (Franke & Shah, 2003; 
Franke, von Hippel & Schreier, 2006; Lüthje, Herstatt & von Hippel, 2002), off-
label drug therapies (Demonaco, Ayfer & von Hippel, 2006), games and toys 
(Stockstrom, Lüthje & Antorini, 2010) as well as banking services (Oliveira & 
von Hippel, 2011). All these studies have proved that users can modify existing 
products and services but also create new ones and provide profitable ideas.
The first question that arises from these wide-ranging examples is 
whether user innovation is a ubiquitous phenomenon. Other cross-industry 
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studies observe how user innovation at firm-level varies widely across 
sector. They also make patent sectoral differences with regard to the levels 
of user innovation (e.g., Flowers, Sinozic & Patel, 2009). Hence, although 
all the aforementioned empirical studies suggest a significant share of 
user innovation over the total of innovation developed in their respective 
areas, the presence of innovative users seems to be more predominant in 
certain sectors than in others like in the healthcare industry. The high level 
of industrial aggregation in certain studies, and the mere absence of the 
healthcare sector in others obscure the understanding of the scope of users’ 
integration in healthcare innovation. In the next subsection we provide some 
examples of patient innovations described in the literature.
Patient as innovator
Recent case studies have corroborated that even patients can innovate and 
promote better health practices. An exploratory empirical analysis identified 
several cases of patient innovation classified into three main categories: 
rare conditions (including rare or orphan diseases), strong constraint on 
daily life and dead end situations (Habicht, Oliveira & Shcherbatiuk, 2012). A 
chest percussion with electrical percussion, electronic trousers ReWalk and 
External Aortic Root Support are some examples of innovations developed 
by patients dealing with adverse health conditions. Indeed, 8% of patients 
with orphan (rare) diseases have developed new to the world innovations 
(Oliveira et al., 2015). Orphan diseases have been widely neglected by the 
pharmaceutical industry due to a lack of financial incentives to work in 
this small and specific market. Therefore, patient solutions have not only 
alleviated and improved the health deficiencies of the self-innovators but 
also those of other patients with similar diseases. A recent empirical research 
pointed out that approximately 88% of those patients who shared their self-
developed solutions shared them with other patients, contrasting, however, 
with only 6% reported to their doctors and clinicians (Oliveira et al., 2015). In 
this sense, patient innovation plays a vital role in the healthcare sector being, 
in certain cases such as orphan diseases, the principal source of hope for the 
treatment of many illnesses.
The internet and new technologies have become the ideal platforms 
for patients to share their experience of existing and original treatments. 
Besides health communities, crowdsourcing sites and smartphone 
applications (in particular healthcare apps) have all become very popular and 
available on different platforms. Apart from individual app developers and 
pharmaceuticals manufacturers, patients have been recognized as important 
innovators of medical smartphone applications. Heath apps developed by 
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patient organizations typically provide emotional support and other patient 
success stories but present only limited functionality such as information, 
social media connections and physician recommendations (IMS Institute 
for Healthcare Informatics, 2013). A recent empirical study based on the 
top 500 apps in Germany, US and UK demonstrated that patient-developed 
apps, as well as applications created by healthcare professionals, have been 
better rated than apps developed by companies or individual developers 
(Goeldner & Herstatt, 2016). In most cases, patients had no external support 
and generated the solutions with their own IT Knowledge. However, most 
of the identified patient-developed apps did not consider regulations. All 
health apps aimed at providing information on a disease or other condition 
are treated as a medical device and subjected to FDA (U.S. Food and Drug 
Administration) regulations (Food and Drug Administration, 2015).
CONCLUSIONS
The objective of this paper is to synthesize part of the existing literature on the 
changing role of users in innovation, with a particular focus on the healthcare 
sector. The so-called user-centered approach suggests a remarkable revolution 
in the way innovation has been conceived. User-centered innovation 
practices have been widely influencing the way new products and services 
are developed in several industries over the last two decades. However, the 
traditional mode of innovation performed by the healthcare industry, which 
is predominantly based on science and technological improvements, casts 
doubt on whether patient-centered innovation can successfully thrive as it 
does in other economic activities. The overdue consideration of the value 
of user involvement - and also of the existence of innovative users - in the 
referred industry could be ascribed to the research-based model that shaped 
innovation in life sciences for a long time. 
The increasing, but still scarce, number of studies dedicated to this topic 
coincides with a new trend where patients play a key role in innovation process 
in both private and public healthcare systems. Experts have demonstrated 
that the close and continuous relationship between patients and healthcare 
professionals can lead to permanent cycles of improvements and innovation 
in healthcare outcomes, including diagnosis, shared decision-making, patient-
centered medical care and patient control. In the context of medical research, 
patients contribute, with their valuable practical experience of dealing daily 
with the effects of certain diseases, to the research design, the analysis of 
research data as well as the dissemination of research findings. 
In spite of that, the definite benefits from a deeper patient engagement 
are still unclear to patients and practitioners in several countries, as proved 
by the Eurobarometer qualitative survey, recently published by the European 
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Commission. Also, patient involvement has mostly been confined to the 
decision making process and the management of chronic diseases, rather 
than a direct cooperation on R&D and innovation projects.
Multi-level collaboration between the healthcare system and other 
economic and societal actors are vital to consolidate a patient-focused care. 
Instead of singular and punctual programs, a fruitful patient-centered model 
would benefit from a multi-level body of governance to operate all kind of 
initiatives including innovation instruments, knowledge management and 
dissemination of eHealth as well as social media. These mechanisms should 
also encourage patient innovation in addition to the diffusion of innovative 
solutions developed by users. The Swedish case cited throughout this article 
is a successful reference in this field. 
This paper also aimed to draw attention to a complementary view, which 
contemplates the user as innovator. There are already numerous examples 
of profitable products, processes and even services originally developed by 
users with different backgrounds and expertise. Although research on lead 
users has been presented over the last three decades, recent publications 
on healthcare have revealed pertinent examples of innovative patients. In 
healthcare, innovative patients are actively developing new solutions for 
their own treatments, likewise for other sick individuals with similar diseases. 
We recommend further research on alternative instruments from public and 
private sectors to stimulate patient innovation mainly in the context of orphan 
diseases, usually overlooked by the pharmaceutical industry due to a lack of 
financial incentives. A shift in the producer-centered innovation approach of 
public policy for healthcare is also needed.
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Abstract (in Polish)
Artykuł zawiera obszerny przegląd literatury na temat zmieniającej się roli 
użytkowników w zakresie innowacji, ze szczególnym naciskiem na sektor opieki zd-
rowotnej. Użytkownicy zostali szczegółowo przeanalizowani przez wielu badaczy na 
całym świecie ze względu na ich istotną rolę jako źródła innowacji, wykraczającą 
poza tradycyjne założenie, które postrzega klientów jako zwykłych i pasywnych 
użytkowników produktów i usług. Zwiększająca się liczba, ale wciąż niewystarczająca, 
wielu badań na ten temat, wykazała korzyści z zaangażowania pacjenta oraz jak blis-
ki i stały związek między pacjentami a lekarzami może prowadzić do trwałych cykli 
ulepszeń i innowacji w zakresie skutków zdrowotnych. Oprócz podejścia zorientow-
anego na użytkownika, innowacyjni pacjenci aktywnie rozwijają nowe rozwiązania 
dla ich własnego leczenia, podobnie jak w przypadku innych pacjentów z podobnymi 
chorobami.
Słowa kluczowe: zaangażowania pacjentów, innowacyjność użytkownika, innowacja 
zorientowana na użytkownika, interaktywne innowacje, innowacje zdrowotne.
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